May 12, 2016
…some studies as an effective treatment for nonalcoholic fatty liver disease (NAFLD) works no better than a placebo, report researchers at University of California San Diego School of Medicine, after conducting the first randomized, double-blind, controlled clinical trial of sitagliptin, an oral antihyperglycemic marketed by Merck & Co. under the…
August 24, 2011
Patients in Nevada seeking care for liver disease may now access the university-level expertise of UC San Diego Health System’s Center for Hepatobiliary Disease and Abdominal Transplantation (CHAT).
October 13, 2011
A collaborative partnership between the UC San Diego Liver Center and Antiviral Research Center (AVRC) has resulted in 19 clinical trials for hepatitis C virus (HCV), focused on developing more effective and well-tolerated HCV treatments.
June 13, 2022
UC San Diego researchers describe connection between pediatric liver disease and increased risk of developing type 2 diabetes. Both rates are rising in children.
August 19, 2016
Researchers at the University of California San Diego School of Medicine have found that a form of magnetic resonance imaging (MRI) that non-invasively measures fat density in the liver corresponds with histological (microscopic tissue analyses) responses in patients with nonalcoholic steatohepatitis (NASH).
February 10, 2016
…itself can directly damage liver cells. Now researchers at University of California, San Diego School of Medicine report evidence that alcohol is also harmful to the liver for a second reason — it allows gut bacteria to migrate to the liver, promoting alcohol-induced liver disease. The study, conducted in mice…
January 5, 2012
A team led by Alan Hemming, MD, transplant surgeon at UC San Diego Health System, has successfully performed the west coast’s first ex-vivo liver resection, a radical procedure to completely remove and reconstruct a diseased liver and re-implant it without any tumors.
April 22, 2024
New research by scientists at University of California San Diego has shown that cells regulate cAMP/PKA signaling by forming liquid droplets that segregate excess PKA catalytic subunits where they can do no harm. Some cancers may block the formation of liquid droplets, leading to hyperactive signaling and tumor formation.
April 15, 2014
Researchers at the University of California, San Diego School of Medicine have identified a mechanism that explains why people with the hepatitis C virus get liver disease and why the virus is able to persist in the body for so long.
August 23, 2023
$9 million grant awarded to researchers with UC San Diego School of Medicine supports new study of semaglutide for liver disease.
